Halozyme Therapeutics, Inc. (0J2O.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 03:02PM BST
| Previous close | 38.89 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 38.92 - 39.54 |
| 52-week range | 30.09 - 44.71 |
| Volume | |
| Avg. volume | 1,670 |
| Market cap | 63.34M |
| Beta (5Y monthly) | 1.25 |
| PE ratio (TTM) | 0.13 |
| EPS (TTM) | 3.00 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksWhy Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ZacksWhy This 1 Value Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
PR NewswireHalozyme to Report First Quarter 2024 Financial and Operating Results
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results on Tuesday, May 7, 2024, following the close of trading.
© 2024 Yahoo. All rights reserved.